AstraZeneca: TEZSPIRE Approved For Self-Administration In The Us With A New Pre-Filled Pen
February 03, 2023
February 03, 2023
WILMINGTON, Delaware, Feb. 3 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
AstraZeneca and Amgen's TEZSPIRE(R) (tezepelumab-ekko) has been approved in the US for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma. TEZSPIRE is the only biologic approved for severe asthma with no phenotype (e.g. eosinophilic or allergic) or biomarker limitation within its approved label.1
The a . . .
AstraZeneca and Amgen's TEZSPIRE(R) (tezepelumab-ekko) has been approved in the US for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma. TEZSPIRE is the only biologic approved for severe asthma with no phenotype (e.g. eosinophilic or allergic) or biomarker limitation within its approved label.1
The a . . .